Dr Kimberley Kaufman

BMedSc (Hons), PhD
Cancer Institute NSW Research Fellow
BrainStorm Brain Cancer Research Group at the Brain and Mind Centre
Manager of RPA Neuropathology Tumour and Tissue Bank
RPA Honorary Research Fellow
School of Life and Environmental Sciences

M02F - 88 Mallett Street - Building F
The University of Sydney

Telephone +61 2 9351 0846

Website BrainStorm, Brain Cancer Research Charity
RPA Neuropathology Department
Level 7 - M02F Mallett Street Campus

Biographical details

I am an Early Career Research Fellow in the School of Life and Environmental Sciences, USYD and an Honorary Associate of the Neuropathology Department, RPAH. I work with the BrainStorm Brain Cancer Research Group at the Brain and Mind Centre. I have contributed to the field of the clinical proteomics for more than 13 years, conducting some of the first human brain proteome studies in 2004.

Research interests

My research utilises cutting-edge mass spectrometry with novel sample preparation procedures to resolve the molecular landscape of cancer. This information can support important clinical questions, e.g., disease stratification, treatment pre-selection and prognostication as well as identify therapeutic targets and chemo-resistance mechanisms. I am active in biomarker research, resolving novel protein markers by quantitative proteomic strategies using surgical tissues, aspirates and peripheral serums.

Current research students

Project title Research student
Proteomic analysis of non-melanoma skin cancer. Ali AZIMI
Modulation of Neuroglia Function by Glioblastoma Stem Cell-derived Extracellular Vesicles Susannah HALLAL

Current projects

My research group is conducting several studies aimed at delineating the roles of extracellular vesicles (EVs) in brain tumour biology.

We are particularly interested in understanding Glioblastoma (GBM), the most common and aggressive brain tumour in adults. Treatment options for GBM patients are extremely limited, and after initial surgery and combined radio- and chemotherapy, tumours inevitably recur, at which point they are rapidly fatal.

EVs, of which ‘exosomes’ are a subset, are stable, virus-sized particles released by all cell types. They contain an array of proteins, nucleic acids, lipids and other metabolites, which reflect the cell of origin but also display selective packaging of some molecules. Interest in the biological roles of EVs, predominantly as novel intercellular communicators, is expanding rapidly and includes direct roles in human pathology e.g., cancer, cardiovascular disease, neurodegeneration and metabolic disease.

GBM-derived EV signalling studies

In gliomas, EVs were identified as key mediators of proliferation and angiogenesis, capable of responding to environmental stimuli, such as hypoxia, and have been shown to not only effect other tumour cells but also healthy tissue, e.g., by inducing angiogenic pathways in nearby endothelial cells. Astrocytes, non-malignant counterparts of GBM cells, are ubiquitous throughout the CNS and are responsible for providing a supportive environment for neurons. Astrocytes become reactive around GBM tumours and previous studies have shown that glioma cells can exploit surrounding non-transformed cells to enhance their invasiveness. Understanding how and what GBM cells communicate to astrocytes to promote tumour invasion is important, as diffuse invasion of the brain parenchyma is a major factor that accounts for the high mortality and morbidity of the disease.

My group has recently shown that GBM-derived EVs are internalized and induce gelatin degradation by increasing podosome/invadopodia formation in normal primary astrocytes in vitro

Interestingly, this effect was more pronounced when astrocytes were exposed to EVs from GBM stem cells (CD133+, Nestin+), compared EVs isolated from differentiated progeny cells (CD133-, nestin-). GBM stem cells possess self-renewal potential and are thought to be responsible for tumour progression and recurrence. Astrocytic projections, or ‘endfeet’ cover about 90% of the blood vessel surface, modulate endothelial tight junctions and secrete vasoactive molecules that regulate vascular tone. The microvasculature is also proposed to be an important scaffold for extravascular tumour migration as well as a pool of readily accessible nutrients. These findings could indicate that GBM EVs aid tumour progression by remodeling astrocyte projections to degrade the extracellular matrix as well as contribute to blood-brain-barrier breakdown, also permitting GBM tumour spread.

To better understand the molecular pathways altered, we performed a quantitative mass spectrometry analysis of astrocytes conditioned with a panel of EVs derived from primary and established GBM cell lines, compared to treated and untreated control cultures. Common protein abundance changes were observed in primary astrocytes following exposure to GBM EVs. Bioinformatics analysis revealed a convergence of protein changes involved in ‘actin-based motility by Rho’ and predicted activation in ‘cellular movement’. Common proteins changes included decreases in SLC3A2 that could mean an imbalance in nutrient cycling in the astrocytes, presenting a strategy to increase extracellular nutrient availability for GBM cells. Further investigations to identify EV induced changes in astrocyte RNA as well as comprehensive profiling GBM EV cargo are underway to understand the impact of EV on tumour biology.

Extracellular Vesicle Biomarker studies

The inability to accurately monitor brain tumoursin situpresents a critical obstacle to the provision of personalised medicine. Unlike other cancers, brain tumours are inaccessible to routine biopsy and neuroimaging is unreliable due to ‘pseudoprogression’, which can give the false appearance of lesion progression, potentially causing initiation of unnecessary treatment. Worse, ‘pseudoresponse’ is a similar phenomenon where tumours may appear to be responding to certain classes of drugs, when in reality their growth patterns have shifted.

Extracellular vesicles (EVs) are unique reservoirs of biomarkersand excitingly, GBM EVs can cross the blood-brain-barrier into the periphery, thereby offering non-invasive access to brain tumour molecules and mutation profiles. With this in mind, the recently popularised idea of a ‘liquid biopsy’ to monitor cancers presents an ideal approach to tackling GBM’s rampant dynamism and aggressiveness. In essence, a liquid biopsy samples peripheral blood for tumour-derived molecules, and uses them to gain insight into the tumour’s behaviour.We have successfully isolated and purified EVs from multiple in vitro and ex vivo sourcesconfirmed by density fractionation, nanoparticle tracking analysis (NTA), transmission electron microscopy (TEM) and identification of specific EV markers.

My group has recently discovered that Cavitron Ultrasonic Surgical Aspirator (CUSA) washes represent a rich source of brain tumour derived EVs. CUSA washings contain tumour tissue fragments that are routinely used in diagnostic pathology; however, the fluid component is typically discarded. These materials are now routinely collected by our biobank through partnerships with RPAH departments Anatomical Pathology and Neurosurgery and the Chris O’Brien Lifehouse.

We are also isolating exosomes from GBM patient sera and performing unbiased sncRNA deep sequencing. Statistical analysis using our established pipeline identified 29 differentially expressed miRNAs in the serum exosomes of GBM patientvs. healthy individuals (n=6; age, sex-matched). Measures of specificity and sensitivity of these differences were impressive: receiver operator characteristic (ROC) area under the curve values were on average >0.93; remarkably, several individual miRNA achieved perfect classification. These data, even while based on small sample size, suggest that serum exosome miRNA has the potential to be a sensitive, specific, diagnostic biomarker for GBM that does not require invasive tumour biopsy. Wewill extend our examination of serum exosome miRNA to a larger cohort of patients in 2018,

Associations

Cancer Insitute NSWNeuro-Oncology Advisory Group, 2015 - current

Brain Cancer Biobanking Australia, 2015 - current

Experimental Neuropathology Affinity Group, Sydney Neuroscience Network, 2015 - current

European Association for NeuroOncology, 2014- current

The Australian and New Zealand Society for Neuropathology, 2014 -2017

NHMRC Research Translation Faculty, 2012 - current

European Association for Cancer Research, 2012 - 2017

Australian Proteomics Society, 2010 – current

Cancer Research Network Sydney University, 2009 - current

Tumour Microenvionment Special Interest Group, 2009 - current

Brain Cancer Special Interest Group, 2014 - current

Sydney Protein Group, 2008 – current

Awards and honours

Outstanding Presentation in Cell Biology Sessionat USYD Cancer Research Network postgraduate and ECR Symposium (supervisor; 2017)

Top 5 presentation at Sydney Catalyst International Translational Research Symposium (2017)

Poster Prize at Lorne Extracellular Vesicles Symposium, Senior Author (2017)

Travel grant ($2500) to present at European Association for NeuroOncology meeting in Italy (2014)

Travel award ($3000) to present at Human Proteome Organisation World Congress in Spain (2014)

Award for outstanding abstract, S.Mactier, K.Kaufman et al., “Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients”,Annual Paris Melanoma Conference (2014)

Fellowship travel grant ($2000) to attend the European Cancer Congress, Netherlands (2013)

Poster prize at Australasian Proteomics Symposium, Senior Author (2013)

Australasian Proteomics Society Early Postdoctoral Fellow Travel Award (2010)

Nerve Research Foundation ‘Bannigan Prize for the Best PhD in Neuroscience’ (2008).

Scholarship for internship at Brain Science Institute, RIKEN, Tokyo, Japan. Supervised by Molecular Psychiatrist, Dr Takeo Yoshikawa (2006).

Bercovici Prize for Excellence in Medical Research’ awarded to the postgraduate with the most outstanding publication at the University of Sydney (2006).

Summer Research Scholarship, Schizophrenia Research Institute (2003 – 2004)

Manager of the RPA Hospital Neuropathology Tumour and Tissue Bank (NTTB).

Themes

Molecular biology and biotechnology; Genetics and genomics; Human health

Selected grants

2014

  • Mechanisms of tumour recurrence and chemotherapy escape in glioblastoma multiforme; Kaufman (nee Alexander) K; Cancer Institute New South Wales/Early Career Fellowship.

2011

  • Surface Antigen Profiles of NeuralEctoderm Tumors:; Kaufman (nee Alexander) K; National Health and Medical Research Council (NHMRC)/Early Career Fellowships.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Matsumoto, I., Kaufman (nee Alexander), K., Matsuda-Matsumoto, H., Kashem, M., Harper, C. (2008). Ethanol-Related Encephalopathies. In GianPietro Sechi (Eds.), Drug related Encephalopathies, (pp. 147-181). New York: Nova Science Publishers.

Journals

  • Mallawaaratchy, D., Hallal, S., Russell, B., Ly, L., Ebrahimkhani, S., Wei, H., Christopherson, R., Buckland, M., Kaufman (nee Alexander), K. (2017). Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease. Journal of Neuro-Oncology, 131(2), 233-244. [More Information]
  • Azimi, A., Kaufman (nee Alexander), K., Ali, M., Kossard, S., Fernandez Penas, P. (2016). In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue. Cancer Genomics & Proteomics, 13(6), 453-466. [More Information]
  • Huang, P., Mactier, S., Armacki, N., Best, O., Belov, L., Kaufman (nee Alexander), K., Pascovici, D., Mulligan, S., Christopherson, R. (2016). Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 57(5), 1033-1043. [More Information]
  • Mallawaaratchy, D., Buckland, M., McDonald, K., Li, C., Ly, L., Sykes, E., Christopherson, R., Kaufman (nee Alexander), K. (2015). Membrane proteome analysis of glioblastoma cell invasion. Journal of Neuropathology and Experimental Neurology, 74(5), 425-441. [More Information]
  • Hare, N., Chan, B., Chan, E., Kaufman (nee Alexander), K., Britton, W., Saunders, B. (2015). Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15. Proteomics, 15(17), 3020-3029. [More Information]
  • Wilcox, P., Li, C., Lee, M., Shivalingam, B., Brennan, J., Suter, C., Kaufman, K., Lum, T., Buckland, M. (2015). Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathologica, 129(1), 147-149. [More Information]
  • Zhou, J., Belov, L., Chapuis, P., Chan, C., Armstrong, N., Kaufman (nee Alexander), K., Solomon, M., Clarke, S., Christopherson, R. (2015). Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. Journal of Immunological Methods, 416, 59-68. [More Information]
  • Kaufman, K., Jenkins, Y., Alomari, M., Mirzaei, M., Best, O., Pascovici, D., Mactier, S., Mulligan, S., Haynes, P., Christopherson, R. (2015). The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget, 6(38), 40981-40997. [More Information]
  • Alomari, M., Mactier, S., Kaufman (nee Alexander), K., Best, O., Mulligan, S., Christopherson, R. (2014). Profiling the lipid raft proteome from human MEC1 chronic lymphocytic Leukemia Cells. Journal of Proteomics & Bioinformatics, S7, 005. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Kaufman (nee Alexander), K., Mactier, S., Armstrong, N., Mallawaaratchy, D., Byrne, S., Haydu, L., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., Christopherson, R. (2014). Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clinical and Experimental Metastasis, 31, 407-421. [More Information]
  • Che, Y., Best, G., Zhong, L., Kaufman (nee Alexander), K., Mactier, S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Mallawaaratchy, D., Mactier, S., Kaufman (nee Alexander), K., Blomfield, S., Christopherson, R. (2012). The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells. Journal of Proteomics, 75(5), 1590-1599. [More Information]
  • Heath, E., Kaufman (nee Alexander), K., Christopherson, R. (2011). B-RAF: A Contributor to the Melanoma Phenotype. The International Journal of Biochemistry and Cell Biology, 43(1), 29-32. [More Information]
  • Zahr, N., Kaufman (nee Alexander), K., Harper, C. (2011). Clinical and pathological features of alcohol-related brain damage. Nature Reviews. Neurology, 7(5), 284-294. [More Information]
  • Kaufman (nee Alexander), K., Belov, L., Huang, P., Mactier, S., Scolyer, R., Mann, G., Christopherson, R. (2010). An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 358(40210 (1-2)), 23-34. [More Information]
  • Kaufman (nee Alexander), K., Harper, C. (2009). Transketolase: Observations in alcohol-related brain damage research. The International Journal of Biochemistry and Cell Biology, 41(4), 717-720. [More Information]
  • Kaufman (nee Alexander), K., Cordwell, S., Harper, C., Matsumoto, I. (2007). A proteome analysis of the dorsolateral prefrontal cortex in human alcoholic patients. Proteomics - Clinical Applications, 1(1), 62-72. [More Information]
  • Kaufman (nee Alexander), K., Harper, C., Wilce, P., Matsumoto, I. (2007). Cerebellar Vermis Proteome of Chronic Alcoholic Individuals. Alcoholism: Clinical and Experimental Research, 31(8), 1286-1296. [More Information]
  • Matsumoto, I., Kaufman (nee Alexander), K., Iwazaki, T., Kashem, M., Matsuda-Matsumoto, H. (2007). CNS proteomes in alcohol and drug abuse and dependence. Expert Review of Proteomics, 4(4), 539-552. [More Information]
  • Kaufman (nee Alexander), K., Dedova, I., Harper, C., Matsumoto, I. (2007). Proteome analysis of the dorsolateral prefrontal region from healthy individuals. Neurochemistry International, 51(6-7), 433-439. [More Information]
  • Matsumoto, I., Kaufman (nee Alexander), K., Harper, C. (2006). Alcohol-induced brain damage: Proteomics on postmortem human brain. Alcoholism: Clinical and Experimental Research, 30(Sup.2), 85A-85A.
  • Kaufman (nee Alexander), K., James, G., Sheedy, D., Harper, C., Matsumoto, I. (2006). Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. Molecular Psychiatry, 11(1), 56-65. [More Information]

Conferences

  • Kaufman (nee Alexander), K., Harper, C., Matsumoto, I. (2006). A proteome analysis of the dorsolateral prefrontal cortex in human alcoholic patients. International Society for Biomedical Research on Alcoholism World congress on Alcohol Research (ISBRA 2006), Maryland: Wiley-Blackwell Publishing.
  • Matsumoto, I., Kaufman (nee Alexander), K. (2006). Alcohol-specific cascades underlying alcohol-induced prefrontal cortex damage: Insight proteomics studies. International Society for Biomedical Research on Alcoholism World congress on Alcohol Research (ISBRA 2006), Maryland: Wiley-Blackwell Publishing.

2017

  • Mallawaaratchy, D., Hallal, S., Russell, B., Ly, L., Ebrahimkhani, S., Wei, H., Christopherson, R., Buckland, M., Kaufman (nee Alexander), K. (2017). Comprehensive proteome profiling of glioblastoma-derived extracellular vesicles identifies markers for more aggressive disease. Journal of Neuro-Oncology, 131(2), 233-244. [More Information]

2016

  • Azimi, A., Kaufman (nee Alexander), K., Ali, M., Kossard, S., Fernandez Penas, P. (2016). In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue. Cancer Genomics & Proteomics, 13(6), 453-466. [More Information]
  • Huang, P., Mactier, S., Armacki, N., Best, O., Belov, L., Kaufman (nee Alexander), K., Pascovici, D., Mulligan, S., Christopherson, R. (2016). Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leukemia & Lymphoma, 57(5), 1033-1043. [More Information]

2015

  • Mallawaaratchy, D., Buckland, M., McDonald, K., Li, C., Ly, L., Sykes, E., Christopherson, R., Kaufman (nee Alexander), K. (2015). Membrane proteome analysis of glioblastoma cell invasion. Journal of Neuropathology and Experimental Neurology, 74(5), 425-441. [More Information]
  • Hare, N., Chan, B., Chan, E., Kaufman (nee Alexander), K., Britton, W., Saunders, B. (2015). Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15. Proteomics, 15(17), 3020-3029. [More Information]
  • Wilcox, P., Li, C., Lee, M., Shivalingam, B., Brennan, J., Suter, C., Kaufman, K., Lum, T., Buckland, M. (2015). Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathologica, 129(1), 147-149. [More Information]
  • Zhou, J., Belov, L., Chapuis, P., Chan, C., Armstrong, N., Kaufman (nee Alexander), K., Solomon, M., Clarke, S., Christopherson, R. (2015). Surface profiles of live colorectal cancer cells and tumor infiltrating lymphocytes from surgical samples correspond to prognostic categories. Journal of Immunological Methods, 416, 59-68. [More Information]
  • Kaufman, K., Jenkins, Y., Alomari, M., Mirzaei, M., Best, O., Pascovici, D., Mactier, S., Mulligan, S., Haynes, P., Christopherson, R. (2015). The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia. Oncotarget, 6(38), 40981-40997. [More Information]

2014

  • Alomari, M., Mactier, S., Kaufman (nee Alexander), K., Best, O., Mulligan, S., Christopherson, R. (2014). Profiling the lipid raft proteome from human MEC1 chronic lymphocytic Leukemia Cells. Journal of Proteomics & Bioinformatics, S7, 005. [More Information]
  • Mactier, S., Kaufman (nee Alexander), K., Wang, P., Crossett, B., Pupo, G., Kohnke, P., Thompson, J., Scolyer, R., Yang, J., Mann, G., Christopherson, R. (2014). Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. Pigment Cell & Melanoma Research, 27(6), 1106-1116. [More Information]
  • Kaufman (nee Alexander), K., Mactier, S., Armstrong, N., Mallawaaratchy, D., Byrne, S., Haydu, L., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., Christopherson, R. (2014). Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients. Clinical and Experimental Metastasis, 31, 407-421. [More Information]

2013

  • Che, Y., Best, G., Zhong, L., Kaufman (nee Alexander), K., Mactier, S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]

2012

  • Mallawaaratchy, D., Mactier, S., Kaufman (nee Alexander), K., Blomfield, S., Christopherson, R. (2012). The phosphoinositide 3-kinase inhibitor LY294002, decreases aminoacyl-tRNA synthetases, chaperones and glycolytic enzymes in human HT-29 colorectal cancer cells. Journal of Proteomics, 75(5), 1590-1599. [More Information]

2011

  • Heath, E., Kaufman (nee Alexander), K., Christopherson, R. (2011). B-RAF: A Contributor to the Melanoma Phenotype. The International Journal of Biochemistry and Cell Biology, 43(1), 29-32. [More Information]
  • Zahr, N., Kaufman (nee Alexander), K., Harper, C. (2011). Clinical and pathological features of alcohol-related brain damage. Nature Reviews. Neurology, 7(5), 284-294. [More Information]

2010

  • Kaufman (nee Alexander), K., Belov, L., Huang, P., Mactier, S., Scolyer, R., Mann, G., Christopherson, R. (2010). An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 358(40210 (1-2)), 23-34. [More Information]

2009

  • Kaufman (nee Alexander), K., Harper, C. (2009). Transketolase: Observations in alcohol-related brain damage research. The International Journal of Biochemistry and Cell Biology, 41(4), 717-720. [More Information]

2008

  • Matsumoto, I., Kaufman (nee Alexander), K., Matsuda-Matsumoto, H., Kashem, M., Harper, C. (2008). Ethanol-Related Encephalopathies. In GianPietro Sechi (Eds.), Drug related Encephalopathies, (pp. 147-181). New York: Nova Science Publishers.

2007

  • Kaufman (nee Alexander), K., Cordwell, S., Harper, C., Matsumoto, I. (2007). A proteome analysis of the dorsolateral prefrontal cortex in human alcoholic patients. Proteomics - Clinical Applications, 1(1), 62-72. [More Information]
  • Kaufman (nee Alexander), K., Harper, C., Wilce, P., Matsumoto, I. (2007). Cerebellar Vermis Proteome of Chronic Alcoholic Individuals. Alcoholism: Clinical and Experimental Research, 31(8), 1286-1296. [More Information]
  • Matsumoto, I., Kaufman (nee Alexander), K., Iwazaki, T., Kashem, M., Matsuda-Matsumoto, H. (2007). CNS proteomes in alcohol and drug abuse and dependence. Expert Review of Proteomics, 4(4), 539-552. [More Information]
  • Kaufman (nee Alexander), K., Dedova, I., Harper, C., Matsumoto, I. (2007). Proteome analysis of the dorsolateral prefrontal region from healthy individuals. Neurochemistry International, 51(6-7), 433-439. [More Information]

2006

  • Kaufman (nee Alexander), K., Harper, C., Matsumoto, I. (2006). A proteome analysis of the dorsolateral prefrontal cortex in human alcoholic patients. International Society for Biomedical Research on Alcoholism World congress on Alcohol Research (ISBRA 2006), Maryland: Wiley-Blackwell Publishing.
  • Matsumoto, I., Kaufman (nee Alexander), K., Harper, C. (2006). Alcohol-induced brain damage: Proteomics on postmortem human brain. Alcoholism: Clinical and Experimental Research, 30(Sup.2), 85A-85A.
  • Matsumoto, I., Kaufman (nee Alexander), K. (2006). Alcohol-specific cascades underlying alcohol-induced prefrontal cortex damage: Insight proteomics studies. International Society for Biomedical Research on Alcoholism World congress on Alcohol Research (ISBRA 2006), Maryland: Wiley-Blackwell Publishing.
  • Kaufman (nee Alexander), K., James, G., Sheedy, D., Harper, C., Matsumoto, I. (2006). Differential protein expression in the prefrontal white matter of human alcoholics: a proteomics study. Molecular Psychiatry, 11(1), 56-65. [More Information]

To update your profile click here. For support on your academic profile contact .